In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

Learn more about whether Alvotech or Grifols, S.A. is a better investment based on AAII's A+ Investor grades, which compare ...

Report commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly ...

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...

Alan Tan, MD, discusses the 8-year follow-up data from the CheckMate 214 trial of patients with advanced renal cell carcinoma.

As of March 21, 2025, we had 2,552,429 Common Shares issued and outstanding. In addition, there were 39,219 Common Shares ...

Shares of Nvidia-backed CoreWeave opened for trading on Friday, raising $1.5B and making it the biggest U.S. tech IPO since 2021, even after ...

Learn more about whether Alvotech or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which ...